Phase II randomized trial of sequentially administered CPT-11 [irinotecan] and mitomycin C in patients with advanced esophageal and stomach cancer.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2012
At a glance
- Drugs Irinotecan (Primary) ; Mitomycin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 27 Jun 2012 Companies (Pharmacia and Pfizer) added and actual patient number changed from 82 to 80 as reported by ClinicalTrials.gov.
- 04 Aug 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 28 Mar 2010 Results published in the Journal of Thoracic Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History